LT4.F LIQUIDIA CORP. DL-001
- Market cap
- EUR 4.45B
- P/E
- -
- P/B
- 20.16x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LT4.F undervalued?
Graham numberThe Graham number of LIQUIDIA CORP. DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LIQUIDIA CORP. DL-001 fundamental analysis
No fundamental analysis for LIQUIDIA CORP. DL-001 yet.
LIQUIDIA CORP. DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LIQUIDIA CORP. DL-001
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered th…
Full company profileLIQUIDIA CORP. DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LIQUIDIA CORP. DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 12.9M | 15.9M | 17.5M | 14.0M | 158M | 706M |
| Gross Profit | 9.83M | 13.1M | 14.6M | 8.12M | 145M | 656M |
| Operating Income | -33.8M | -38.8M | -73.4M | -121M | -51.4M | 364M |
| EBITDA | - | -35.0M | -70.1M | -111M | -43.2M | -148M |
| Net Income | -34.6M | -41.0M | -78.5M | -128M | -68.9M | -145M |
| EPS | -0.66 | -0.64 | -1.14 | -1.51 | -0.79 | -1.62 |
| Balance Sheet | ||||||
| Total Assets | 93.7M | 129M | 118M | 230M | 328M | 683M |
| Total Liabilities | 28.5M | 38.8M | 71.0M | 153M | 283M | 708M |
| Shareholders' Equity | 65.3M | 90.4M | 47.3M | 77.3M | 44.7M | -25.4M |
| Cash & Short-term Investments | 57.5M | 93.3M | 83.7M | 176M | 191M | 396M |
| Cash Flow | ||||||
| Operating Cash Flow | -34.0M | -28.6M | -41.6M | -93.4M | -35.7M | 373M |
| Capital Expenditure | 107K | 592K | 11.3M | 8.45M | 6.34M | 42.6M |
| Free Cash Flow | -34.1M | -29.2M | -52.9M | -102M | -42.0M | 331M |
| Ratios | ||||||
| ROE | -53.0% | -45.4% | -166.0% | -166.0% | -154.0% | - |
| ROA | -36.9% | -31.7% | -66.3% | -55.7% | -21.0% | -21.2% |
| Net Profit Margin | -269.0% | -257.4% | -448.9% | -916.6% | -43.5% | -20.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LIQUIDIA CORP. DL-001 dividends
LIQUIDIA CORP. DL-001 has not paid dividends in the last 5 fiscal years.
Who owns LIQUIDIA CORP. DL-001
- Insiders 9.15%
- Institutions 81.42%
- Public & others 9.43%
- Shares outstanding 90.1M
- Free float 65.6M
LIQUIDIA CORP. DL-001 company profile
- Company name
- LIQUIDIA CORP. DL-001
- Ticker
- LT4.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 216
- Fiscal year end
- December
- Address
- 419 Davis Drive, Morrisville, NC, United States, 27560
- Phone
- 919 328 4400
- Website
- liquidia.com
About LIQUIDIA CORP. DL-001
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
LIQUIDIA CORP. DL-001 management
10- Dr. Roger A. Jeffs Ph.D.CEO & Director · born 1962
- Mr. Michael KasetaCOO & CFO · born 1976
- Mr. Russell SchundlerGeneral Counsel & Corporate Secretary · born 1976
- Mr. Scott MoomawChief Commercial Officer · born 1971
- Dr. Rajeev Saggar M.D.Chief Medical Officer · born 1975
- Ms. Dana BoyleChief Accounting Officer · born 1985
- Mr. Christian Perez FontSenior VP, Chief Compliance Officer & Associate General Counsel
- Mr. Michael PostSenior Vice President of Marketing
- Mr. Matt SnowSenior Vice President of Sales
- Ms. Sarah Krepp SPHRChief Human Resources Officer · born 1982